tradingkey.logo

Xtandi® Plus Leuprolide Significantly Improves Survival Outcomes In Men With Non-Metastatic Hormone-Sensitive Prostate Cancer With High-Risk Biochemical Recurrence

ReutersJul 10, 2025 10:52 AM

- Pfizer Inc PFE.N:

  • XTANDI® PLUS LEUPROLIDE SIGNIFICANTLY IMPROVES SURVIVAL OUTCOMES IN MEN WITH NON-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER WITH HIGH-RISK BIOCHEMICAL RECURRENCE

  • PFIZER: EMBARK MET KEY SECONDARY ENDPOINT

  • PFIZER INC - XTANDI PLUS LEUPROLIDE IMPROVES OVERALL SURVIVAL

  • PFIZER: NO NEW SAFETY SIGNALS WERE OBSERVED IN ANALYSIS, AND SAFETY RESULTS WERE CONSISTENT WITH DEMONSTRATED SAFETY PROFILE OF XTANDI

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI